MarketPulse
T

$TCRX

3 articles found
3 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Posts $28.7M Q1 Loss as Pipeline Advances Toward Phase 3

TScan Therapeutics reports $28.7M Q1 loss, $1.0M revenue; $128.1M cash funds operations to H2 2027 amid Phase 3 pipeline advancement.
TCRXclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Advances TCR Cell Therapy Pipeline With FDA Clearance, Conference Participation

TScan Therapeutics secures FDA clearance for two IND applications and completes Phase 1 trial enrollment using commercial-scale manufacturing, advancing its TCR cell therapy pipeline.
TCRXclinical-stage biotechsolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Na

TScan Advances Allogeneic Cell Therapy Pipeline With FDA IND Clearances and Trial Enrollment Milestones

TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.
TCRXclinical trialTCR-T therapy